Donald A. Mahler

TL;DR: The relations among descriptors of breathlessness obtained in healthy individuals support the contention that the association of different clusters with different disease states reflects distinct and separable cognitive constructs that are not simply dependent on the presence of an underlying pathophysiology or on a specific disease condition.

TL;DR: Observational studies demonstrate that 19 to 78% of stable outpatients with chronic obstructive pulmonary disease and 32 to 47% of inpatients prior to discharge after admission for an exacerbation have a suboptimal peak inspiratory flow rate, and data suggest that peak inspiratories flow rate should be measured against the simulated resistance of the specific dry powder bronchodilator device prior to prescription.

TL;DR: The validity of the TDI is supported in a large clinical trial setting after a retrospective analysis of data from a randomized, double-blind placebo-controlled clinical trial of chronic obstructive pulmonary disease patients.

TL;DR: It is reasonable to measure a patient's PIFR against the simulated resistance of a specific DPI if there is concern about clinical benefit using the dry powder medication, and assess test-retest reliability of PifRresist.

TL;DR: Patients with chronic obstructive pulmonary disease (COPD) describe their breathlessness as related to the work and effort associated with breathing, and patient-reported dyspnea based on activities of daily living and exercise testing provides distinct but complimentary information.